1.07 million consumables or price reduction of more than 88% of the market pattern or little change.

Pharma Network October 22nd, the national price reduction or more than 88% Recently, Tianjin Pharmaceutical Purchasing Center issued the "National Organization Crown Bracket Concentrated Band Purchase Document (GH-HD2020-1)" (hereinafter referred to as "Band Purchase Document"), began to material cobalt chromium alloy or platinum chromium alloy, the type of drug carrier is repamycin and its derivatives of the coronary stent with volume procurement.
According to Cypress Blue equipment combing, this intention to purchase products including minimally invasive medical, Lepu Medical, Shandong Jiwei, Poco, Medtron, Abbott and other well-known domestic and foreign armed enterprises, the total number of intention to purchase brackets 1074722.
it is worth noting that this may be the right to select the qualification, requiring enterprises to declare the price≤ the minimum product declaration price of 1.8 times, or the declared price of the lowest product declaration price of 1.8 times, but less than 2850 yuan.
Synda Securities pharmaceutical industry chief analyst Yang Song on the Cypress Blue device analysis, no more than 1.8 times the minimum product declaration price of this requirement is a reference to the drug belt procurement rules, can effectively avoid the problem of large price difference between products, if the final price difference is too large, clinical use may appear to choose high-priced products, resulting in the volume of procurement policy effect "discount."
In addition, another rule of the ceiling price of 2850 yuan is a reference to Jiangsu drug eluted crown stent Lepu Medical a crown stent of the lowest negotiated price, according to the "a big pine tree" public number combing, the current minimally invasive medical, Lepu Medical, Medtron, Abbott, Poco, Shandong Jiwei and other equipment products hanging network prices from 7600 yuan to 23,500 yuan.
drop from 23,500 yuan to 2850 yuan, the decline will reach 88%, and 2850 yuan is only the price ceiling of this negotiation.
understood that before this has been Shanxi, Jiangsu to complete the crown bracket with the volume of procurement.
In June this year, according to Shanxi Provincial Health Insurance Bureau official micro-news, 31,693 crown bracket belt volume procurement results announced, Medtron, Abbott, Lepu, Shanghai Micro-Creative, Shandong Jiwei and other weapons products selected, the average price fell by 52.98 percent, the highest decline of 69.12 percent, the lowest decline of 40.2 percent.
July 31, 2019, according to the Nanjing Daily News, the results of the first consumables alliance negotiations in Jiangsu Province were announced, the negotiating varieties are repamycin and its derivative stents and double-cavity pacemakers.
the brackets were negotiated by individual varieties, the average decline of the selected varieties was 51.01%, with a maximum decrease of 66.07%.
The market pattern or change not much after each large-scale volume procurement, the industry is most concerned about the change of the market pattern - whether there will be a dark horse, the original head of the enterprise status will change, from this volume procurement, perhaps to a certain extent tend to maintain the existing clinical end-market pattern unchanged.
According to the "strip procurement documents", before bidding, has determined the intention to purchase varieties and procurement volume, more notably, "with volume procurement documents" requirements, for the selected product agreement procurement volume, medical institutions to report the demand for products in the selected range, the corresponding intention to purchase all included in the selected product agreement procurement volume.
the first winner not necessarily get the most purchases? Yang Song on the Cypress blue device analysis, in fact, this rule itself is not very much hope that the lowest price to take away most of the purchase volume, but tend to ensure that the clinical terminal pattern remains unchanged.
For enterprises, if the product is selected, then the original market share and channels can be preserved, according to the rules, enterprises want to keep the stock to be selected, want to be selected to reduce prices, so the pressure to reduce prices will also increase.
At the same time, this rule also avoids the selection of barefoot enterprises, on the one hand, barefoot enterprises themselves the market stock is very small, this part of the selection will not be too large, on the other hand, even if you get the increment, according to the rules will not be too large.
In addition, the Volume Purchase Document also requires that the product portion of the proposed product be selected, and in the event of the same declared price, the ranking shall be determined in turn according to the following rules: (1) products with high sales in 2019 are preferred;
to this, Yang Song said, the use of large-scale proof of high market recognition, according to the first registration card time is because the longer the time used in the market, the greater the use, the more security can be guaranteed.
there is also a factor that newly approved products may perform better and perform better, and from this point of view, documentation rules may still tend not to have much impact on the existing market landscape.
.